Ontak (denileukin diftitox, from Eisai) has received full FDA approval for the treatment of persistent or recurrent cutaneous T-cell lymphoma (CTCL) in which malignant cells express the CD25 component of the interleukin (IL)-2 receptor (CD25+). In a randomized, double-blind clinical trial of 144 patients, Ontak-treated patients had significantly higher overall response rates (ORR) and progression-free survival (PFS) percentages compared to placebo.

For more information call (877) 873-4724 or visit www.eisai.com/section.asp?ID=257.